Stryker Co. (NYSE:SYK) Shares Sold by CWS Financial Advisors LLC

CWS Financial Advisors LLC decreased its holdings in Stryker Co. (NYSE:SYK) by 0.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 256,581 shares of the medical technology company’s stock after selling 713 shares during the quarter. Stryker accounts for about 29.9% of CWS Financial Advisors LLC’s holdings, making the stock its largest holding. CWS Financial Advisors LLC owned 0.07% of Stryker worth $92,382,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Dunhill Financial LLC raised its holdings in shares of Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 37 shares during the last quarter. Centricity Wealth Management LLC acquired a new position in shares of Stryker during the fourth quarter valued at approximately $30,000. BankPlus Trust Department acquired a new position in shares of Stryker during the fourth quarter valued at approximately $33,000. Darwin Wealth Management LLC acquired a new position in shares of Stryker during the third quarter valued at approximately $36,000. Finally, Activest Wealth Management acquired a new position in shares of Stryker during the fourth quarter valued at approximately $36,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the subject of a number of research analyst reports. Citigroup increased their target price on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. UBS Group upped their price target on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. The Goldman Sachs Group upped their price target on Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a research report on Thursday, January 30th. Stifel Nicolaus upped their price target on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Finally, Argus set a $450.00 price target on Stryker in a research report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $422.15.

Stryker Stock Up 1.4 %

Shares of NYSE SYK opened at $388.11 on Tuesday. The stock has a market cap of $148.09 billion, a P/E ratio of 50.01, a PEG ratio of 2.93 and a beta of 0.96. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The business’s fifty day simple moving average is $378.38 and its 200-day simple moving average is $369.78.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the company earned $3.46 EPS. As a group, equities analysts predict that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.87%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is currently 43.30%.

Insider Activity

In other Stryker news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.